A STUDY OF THE EFFECTIVENESS OF A CARCINOSTATIC AND INCREASING GARCINOSTATIC TOLERANCE

研究背景化疗耐药可分为膜耐药和酶耐药。已经进行了研究来阐明这些耐药现象并开发新的治疗剂，但结果还不完全令人满意。一些药物由于其治疗效果而经常使用，但最终出现的耐药性需要使用多种药物并努力对抗多种不良反应。因此，还进行了研究，以通过联合使用抗生素和非抗生素来克服耐药性。如果在化疗药物出现耐药性之前抑制耐药性或延迟耐药性的发展，而不是研究已经产生耐药性的癌症，则可以预期治疗方式会产生更有效的结果。本研究正是基于这一观点进行的。研究的过程和结果 ...更多信息 艾德的药物和非药物。用阿霉素免疫家兔，成功地制备了阿霉素抗体。通过使用这种针对抗肿瘤剂的抗体，我们期望有意地抑制已经施用的抗肿瘤剂的活性，从而实现更有效的化疗。在动物实验中，我们观察到明显的增效作用的药物。此外，这种设计的失活能够减少药物的不良反应。ADM最突出的不良反应是心脏毒性，联合使用抗阿霉素抗体，允许给予更大剂量的阿霉素，可改善心脏毒性。(1)使用ADM制备抗体。所得抗ADM抗体是分子量为150，000的多克隆IgG抗体，其对ADM具有特异性。(2)尽管细胞膜和Co-Q10中存在泛醌环（例如ADM的泛醌环），但抗ADM抗体与ADM的反应缺乏交叉反应性和特异性。(3)应用抗阿霉素抗体免疫组化观察阿霉素在癌组织中的定位。(4)癌组织细胞膜糖链抗原的变化及定位研究。(5)抗阿霉素抗体对阿霉素药理作用的灭活研究报告。(6)对大鼠重复施用抗ADM抗体。确认抗体在治疗移植性肿瘤中的功效。少

Background of the studyDrug resistance in chemotherapy can be pharmacologically classified into one based on membrane resistance and another based on enzyme resistance . Studies have been conducted to elucidate these resistance phenomena and develop new therapeutic agents but the outcomes are not yet totally satisfactory. Some drugs are employed frequently due to their therapeutic efficacy but the eventual emergence of resistance necessitates the use of multiple agents and efforts to confront the multiple adverse affects. Thus studies have also been conducted to overcome resistance by the combined use of both antineoplastic and non-antineoplastic agents. A more effective outcome may be expected from the therapeutic modality if resistance is suppressed or its development delayd before the antineoplastic agents meet resistance, rather than investigating cancer that has already developed resistance. Our study was based on this viewpoint.Process and outcome of the studyIn this study, we us … More ed antineoplastic and non-antineoplastic agents. We succeeded in preparing an antibody by immunizing rabbits against ADM (adriamycin). By using this antibody directed against the antineoplastic agent, we expected to inactivate intentionally the activity of the antineoplastic agent that has been administered, thus achieving a more effective chemotherapy. In animal experiments, we observed evident potentiation of the effect of the antineoplastic agent. Furthermore this designed inactivation enabled rerductions in the adverse effects of the antineoplastic agent. The most out-standing adverse effect related to ADM is cardiotoxicity, which was amelioratedby the combined use of anti-adria-mycin antibody, permitting administration of a greater dosage of the antineoplastic agent.(1) Preparation of an antibody by using ADM.The resultant anti-ADM antibody is a polyclonal IgG antibody with a molecular weight of 150,000, which has a specificity to ADM.(2) A lack of cross reactivity and the specificity of the reaction of the anti-ADM antibody to ADM, in spite of the presence of the ubiquinone rings, such as that of ADM, in the cell membrane and Co-Q10.(3) Immunohistochemical observation of the localization of ADM in the cancerous tissue, by using the anti-ADM antibody.(4) A study on changes and localization of carbohydrate chain antigens in the cell membrane of cancerous tissue.(5) Report on the research on inactivation of the pharmacological action of ADM by the anti-ADM antibody.(6) Repeated administration of the anti-ADM antibody to rats. Confirmation of the efficacy of the antibodies in the treatment of transplanted neoplasms. Less